Prevention

Introduction

The survey assessed the feasibility of programmatic use of Lfx for TPT among contacts of MDR-TB patients in the eventuality of a WHO recommendation for its programmatic use. The objective was to collect perspectives from national TB programmes (NTPs), explore current practices for MDR TPT, its programmatic feasibility, affordability, impact on equity, acceptability to patients and health-care workers and to inform the discussion of WHO Guideline group at its meeting on 4–6December 2023.

Methods

Objective: to assess the values, preferences, acceptability and feasibility of Lfx as TPT for adult HHCs of patients diagnosed with MDR-TB in five low- and middle-income countries: Georgia, India, Indonesia, South Africa and Viet Nam.

Harsimren Sidhu, Siobhan Carroll, Dick Menzies⁹

Introduction

Tuberculosis Child Multidrug-Resistant Preventive Therapy Trial (TB CHAMP): Efficacy and safety of levofloxacin preventive treatment in child and adolescent HHCs of multidrug-resistant tuberculosis (MDR-TB). Author: Anneke Hesseling⁷

V-QUIN MDR-TB prevention study: Levofloxacin versus placebo for the treatment of tuberculosis infection among contacts of patients with MDR-TB. Author: Greg Fox⁸

Methods

Older terminology used in the context of TB preventive treatment (TPT), such as latent TB infection (LTBI) and active TB, has been retained in the original text of the tables.

PICO 1: What is the prevalence of TB infection, risk of progression to TB disease and cumulative prevalence of TB disease among household contacts without HIV in different age groups in high TB incidence countries?

Older terminology used in the context of TPT, such as latent TB infection (LTBI) and active TB, has been retained in the original text of the tables.

Is the prevalence of TB disease and TB infection higher among household contacts without HIV than in the general population in different age groups in high TB incidence countries?

Web Annex B. Conflict of interest assessment for experts contributing to the handbook content https://doi.org/10.2471/B09117

Web Annex A. Pharmacokinetics modelling and simulation studies for dosages of 6Lfx and 3HP https://doi.org/10.2471/B09127